Spero Therapeutics news centers on its work as a clinical-stage biopharmaceutical company focused on immunology and inflammation. Company updates often address SP001, its third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease.
Other important Spero news relates to Utebzi, the Spero-developed oral antibiotic licensed to GSK for most territories and to Meiji for certain Asian territories. Updates may involve FDA-related disclosures, partner-linked commercialization rights, milestone and royalty arrangements, and financing backed by portions of future Utebzi payments.
Spero also issues news on quarterly operating results, business updates, healthcare conference presentations, executive and clinical leadership appointments, and inducement equity grants under Nasdaq listing rules. These categories reflect both its drug-development pipeline and its public-company reporting obligations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. Management will present from 10:30 AM to 11:00 AM ET and is available for one-on-one meetings. Key products include SPR720, targeting non-tuberculous mycobacterial infections, and Tebipenem HBr, an investigational drug for complicated urinary tract infections (cUTI). Spero is also developing SPR206, an IV-administered candidate for multi-drug resistant Gram-negative infections. Investors can access the webcast through the Spero website after the event. The company focuses on addressing rare diseases and multi-drug resistant bacterial infections with promising therapies.
Spero Therapeutics (Nasdaq: SPRO) announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The presentations, both authored by RE Mendes, Ph.D., focus on the in vitro activity of SPR206 against bacterial infections, highlighting its potential against Enterobacterales and Pseudomonas aeruginosa isolates in Europe. These studies underscore Spero's commitment to addressing multi-drug resistant (MDR) infections and developing effective treatments. The research was sponsored by Spero and supported by the Office of the Assistant Secretary of Defense for Health Affairs. For more details, visit Spero's official site for key publications and presentations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of 95,000 restricted stock unit awards (RSUs) to four new employees as part of the 2019 Inducement Equity Incentive Plan. This decision, made on March 23, 2023, aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four annual installments starting April 3, 2024, contingent on the employees' continued employment. Spero Therapeutics focuses on developing treatments for rare diseases and multi-drug resistant infections, with ongoing projects such as SPR720 and tebipenem HBr.